BI
LXRX icon

BVF Inc’s Lexicon Pharmaceuticals LXRX Stock Holding History

BVF Inc’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,686,924
Closed -$4.05M – 65
2024
Q1 		$4.05M Sell
1,686,924
-22,748,708
-93% -$48.9M 0.11% 50
2023
Q4 		$37.4M Buy
24,435,632
+4,440,300
+22% +$5.28M 0.94% 28
2023
Q3 		$21.8M Hold
19,995,332
– – 0.59% 33
2023
Q2 		$45.8M Buy
19,995,332
+3,846,153
+24% +$10.2M 1.28% 23
2023
Q1 		$39.2M Hold
16,149,179
– – 1.43% 23
2022
Q4 		$30.8M Hold
16,149,179
– – 1.3% 28
2022
Q3 		$38.8M Buy
16,149,179
+2,000,000
+14% +$5.54M 1.6% 22
2022
Q2 		$26.3M Sell
14,149,179
-207,410
-1% -$396K 1.27% 27
2022
Q1 		$30M Sell
14,356,589
-3,411
-0% -$9.46K 1.2% 26
2021
Q4 		$56.6M Hold
14,360,000
– – 2.05% 15
2021
Q3 		$69.1M Buy
14,360,000
+5,966,000
+71% +$24.5M 2.69% 10
2021
Q2 		$38.5M Hold
8,394,000
– – 1.44% 17
2021
Q1 		$49.3M Sell
8,394,000
-2,569,000
-23% -$17.8M 1.85% 17
2020
Q4 		$37.5M Buy
+10,963,000
New +$20.9M 1.48% 23

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BVF Inc's LXRX Position: Q2 2024 in Review

BVF Inc sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2024, closing a stake of 1,686,924 shares — an estimated $4.05M sold.

BVF Inc first reported a position in LXRX in Q4 2020 and held it in 14 quarters. The position peaked at $69.1M in Q3 2021. 127 funds tracked by Wall St. Rank hold LXRX as of Q2 2024.

  • BVF Inc reported no remaining Lexicon Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • BVF Inc sold 1,686,924 Lexicon Pharmaceuticals shares in Q2 2024, an estimated $4.05M.
  • BVF Inc first reported a position in Lexicon Pharmaceuticals in Q4 2020 and held it in 14 quarters.
  • BVF Inc's Lexicon Pharmaceuticals position peaked at $69.1M in Q3 2021.
  • 127 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2024.

Based on BVF Inc's 13F filing for Q2 2024, filed 14 Aug 2024.